| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 717 | 2021 |
| ACE2gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population E Benetti, R Tita, O Spiga, A Ciolfi, G Birolo, A Bruselles, G Doddato, ... European Journal of Human Genetics, 2020 | 270 | 2020 |
| Whole-genome sequencing reveals host factors underlying critical COVID-19 A Kousathanas, E Pairo-Castineira, K Rawlik, A Stuckey, CA Odhams, ... Nature 607 (7917), 97-103, 2022 | 222 | 2022 |
| Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study C Fallerini, S Daga, S Mantovani, E Benetti, N Picchiotti, D Francisci, ... elife 10, e67569, 2021 | 172 | 2021 |
| Comparison of right versus left ventricular strain analysis as a predictor of outcome in patients with systolic heart failure referred for heart transplantation M Cameli, FM Righini, M Lisi, E Bennati, R Navarri, S Lunghetti, ... The American journal of cardiology 112 (11), 1778-1784, 2013 | 102 | 2013 |
| Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19 M d'Alessandro, P Cameli, RM Refini, L Bergantini, V Alonzi, N Lanzarone, ... Journal of medical virology 92 (10), 2216-2220, 2020 | 97 | 2020 |
| Oxidant/antioxidant disequilibrium in idiopathic pulmonary fibrosis pathogenesis P Cameli, A Carleo, L Bergantini, C Landi, A Prasse, E Bargagli Inflammation 43, 1-7, 2020 | 70 | 2020 |
| COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs E Conticini, E Bargagli, M Bardelli, GD Rana, C Baldi, P Cameli, ... Annals of the rheumatic diseases, 2020 | 67 | 2020 |
| Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6 L Bergantini, F Bianchi, P Cameli, MA Mazzei, A Fui, P Sestini, P Rottoli, ... Disease Markers 2019, 2019 | 62 | 2019 |
| Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis D Bennett, P Cameli, N Lanzarone, L Carobene, N Bianchi, A Fui, L Rizzi, ... Respiratory research 21, 1-12, 2020 | 61 | 2020 |
| Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study P Cameli, RM Refini, L Bergantini, M d’Alessandro, V Alonzi, C Magnoni, ... Frontiers in Molecular Biosciences 7, 581828, 2020 | 60 | 2020 |
| BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases M d’Alessandro, A Carleo, P Cameli, L Bergantini, A Perrone, L Vietri, ... Clinical and Experimental Medicine 20, 207-216, 2020 | 60 | 2020 |
| Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males M Baldassarri, N Picchiotti, F Fava, C Fallerini, E Benetti, S Daga, ... EBioMedicine 65, 2021 | 59 | 2021 |
| Usefulness of echocardiography to detect cardiac involvement in COVID‐19 patients M Cameli, MC Pastore, H Soliman Aboumarie, GE Mandoli, F D'Ascenzi, ... Echocardiography 37 (8), 1278-1286, 2020 | 56 | 2020 |
| Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review M d’Alessandro, L Bergantini, P Cameli, L Vietri, N Lanzarone, V Alonzi, ... Biomarkers in Medicine 14 (8), 665-674, 2020 | 55 | 2020 |
| Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life B Sposato, G Camiciottoli, E Bacci, M Scalese, GE Carpagnano, C Pelaia, ... Pulmonary pharmacology & therapeutics 61, 101899, 2020 | 54 | 2020 |
| Left atrial strain as a pre-operative prognostic marker for patients with severe mitral regurgitation GE Mandoli, MC Pastore, G Benfari, G Bisleri, M Maccherini, G Lisi, ... International journal of cardiology 324, 139-145, 2021 | 53 | 2021 |
| Effects of rituximab therapy on B cell differentiation and depletion L Bergantini, M d’Alessandro, P Cameli, L Vietri, C Vagaggini, A Perrone, ... Clinical Rheumatology 39, 1415-1421, 2020 | 53 | 2020 |
| Serum amyloid A: A potential biomarker of lung disorders L Vietri, A Fui, L Bergantini, M d’Alessandro, P Cameli, P Sestini, P Rottoli, ... Respiratory Investigation 58 (1), 21-27, 2020 | 49 | 2020 |
| Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting M d'Alessandro, F Perillo, RM Refini, L Bergantini, F Bellisai, E Selvi, ... International Immunopharmacology 86, 106748, 2020 | 48 | 2020 |
